The clinical usefulness of a self-administered questionnaire for sleep-disordered breathing in patients with neuromuscular disease

Cathy Zhang1, Michelle Ramsay1,2, Panagis Drakatos2, Joerg Steier1,2

1Faculty of Life Sciences and Medicine, King’s College London, London, UK; 2Guy’s and St Thomas’ NHS Foundation Trust, Lane Fox Respiratory Unit/Sleep Disorders Centre, London, UK

Contributions: (I) Conception and design: C Zhang, M Ramsay, J Steier; (II) Administrative support: J Steier; (III) Provision of study materials or patients: J Steier, M Ramsay; (IV) Collection and assembly of data: M Ramsay, P Drakatos, J Steier; (V) Data analysis and interpretation: C Zhang, M Ramsay, J Steier; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Background: Patients with neuromuscular disease (NMD) are at risk of developing sleep-disordered breathing (SDB) with hypercapnic respiratory failure. We hypothesised that a self-administered questionnaire (SiNQ-5 scores) may be useful to assess patients who are established on treatment for NMD with SDB.

Methods: Patients attending a tertiary referral centre filled in the SiNQ-5 (range 0–10 points, lower scores indicating fewer symptoms). The questionnaire contains five questions related to breathlessness, sleep and posture. Patients with NMD and treated SDB were compared to NMD without SDB, to sleep apnoea, chronic obstructive pulmonary disease (COPD) and heart failure (HF) patients’ scores, as well as a group of patients without SDB. Results were compared using Kruskal-Wallis one-way analysis of variance, with Dunn/Bonferroni post-hoc tests if comparisons were found to be statistically significant.

Results: A total of 265 (156 male) patients completed the assessment, 40 had NMD with treated SDB [SiNQ-5 score 3.4 (3.0) points], 11 had NMD without SDB [2.7 (2.9) points], 120 patients had obstructive sleep apnoea (OSA) [4.1 (2.6) points], 16 had COPD [3.9 (3.0) points] and 9 had HF [3.2 (2.8) points], 69 patients had other conditions with no evidence of SDB [3.0 (2.4) points; P=0.077]. Patients with NMD without SDB and those with SDB who were on treatment did not differ in their responses (P=0.417). Question #1 allowed discrimination between patients with NMD with SDB [0.8 (0.8) points] and other disorders without respiratory involvement [0.3 (0.6) points; P=0.024].

Conclusions: The SiNQ-5 scores in neuromuscular patients with SDB who are established on treatment and NMD patients without SDB, as well as in patients with other conditions leading to SDB are similar.

Keywords: SiNQ-5; diaphragm weakness; Epworth Sleepiness Scale (ESS); respiratory failure; sleep apnoea

Submitted Apr 04, 2017. Accepted for publication May 17, 2017.
doi: 10.21037/jtd.2017.06.40
View this article at: http://dx.doi.org/10.21037/jtd.2017.06.40
(SDB) is a complication which contributes significantly to morbidity and mortality (1,3,4). Indeed, undetected SDB can eventually progress to hypercapnic respiratory failure and death (2).

Daytime fatigue and tiredness are cardinal symptoms associated with sleep disturbance (2). Questionnaires like the Epworth Sleepiness Scale (ESS) have been developed to screen for patients with obstructive sleep apnoea (OSA) and associated daytime symptoms (5). However, the ESS has not been designed to identify patients with SDB due to underlying NMD. In particular, individuals in early stages of SDB due to NMD might be breathless and not sleepy and, therefore, may not be reliably identified by the ESS, although available treatment with non-invasive ventilation (NIV) could provide an early benefit (6,7).

To establish the diagnosis of SDB in NMD patients, polysomnography (PSG) and arterial blood gas analysis provide the most reliable method. Indeed, PSG is currently considered as the “gold standard” to diagnose SDB (1,4,8-12). However, the sophisticated setup, the required expertise and the associated costs limit the availability of PSG facilities for adult (13,14) and paediatric (12) patients. Consequently, there is a clinical need to screen for patients with NMD at risk of developing SDB due to respiratory muscle weakness using other available tools and to triage patients at risk for further investigation using PSG. For this purpose, a questionnaire, the ‘SDB in Patients with NMD’ questionnaire (SiNQ-5), has previously been developed and validated using PSG and invasive tests of respiratory muscle strength in patients with NMD and SDB (10).

Following the successful validation of the SiNQ-5 in identifying NMD patients with untreated SDB compared to SDB and healthy subjects, we hypothesised that the SiNQ-5 scores of patients with NMD and treated SDB, would be similar to the scores of NMD patients without SDB and those with OSA, chronic obstructive pulmonary disease (COPD), heart failure (HF) and patients with non-respiratory sleep disorders.

Methods

Consecutive patients from respiratory outpatient settings, the Lane Fox Unit, and the sleep services within Guy’s and St Thomas’ NHS Foundation Trust, London, UK were selected during a 1-year period (01/2011–01/2012). The study was registered as a clinical service evaluation with the local clinical governance committee (registration number with local board: 2012-2979); informed, verbal consent was obtained from all participants. All patient details were anonymised and treated with confidentiality. Based on pre-existing diagnoses, patients were categorised into the following subgroups: NMD with and without SDB, OSA, COPD, HF, and patients with other conditions, which included individuals with non-respiratory sleep disorders (such as narcolepsy, insomnia and parasomnia) and snorers without SDB. Patients with COPD and HF were stable and at optimised treatment. Clinical information regarding treatment with continuous positive airway pressure (CPAP) or NIV, along with the presence or absence of SDB were collected. A diagnosis of SDB was made based on the results of the overnight sleep study results; an apnoea hypopnoea index (AHI) or an oxygen desaturation index (4% ODI) >5/h, or a total sleep time with SpO_2 <90% of more than 10% of the night were defined as sleep disordered breathing (8,15).

SiNQ-5

A printed copy of the self-administered 5-item SiNQ-5, each item to be scored between 0 and 2 (total range 0–10 points, a score >5 points indicating increased likelihood of associated SDB) was given to each patient to complete in their own time (10). Responses to the SiNQ-5 were not associated SDB) was given to each patient to complete in their own time (10). Responses to the SiNQ-5 were not influenced by clinicians or family members; an exception to this was made when patients experienced problems understanding the content of the questionnaire and required further clarification.

ESS

A subgroup of patients completed the ESS, a self-administered questionnaire designed to measure daytime sleepiness in eight common situations (5). Each item of the ESS was scored on a scale from 0 to 3, allowing for a total score of 0 to 24 points; a score ≥10 points identified patients with excessive daytime sleepiness. The questionnaire had originally been developed and validated for screening of daytime sleepiness in patients with OSA (5), but is also widely used to screen for other conditions causing excessive sleepiness in the general population (16).

Statistical analysis

Data were collected, tabulated and analysed using MS Excel 2016 (Microsoft Corporation, Seattle/WA, USA) and IBM SPSS statistics version 23 (IBM, New York/NY, 2018).
Table 1: Demographic data classified into groups by diagnosis (n=265)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Age (years)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Male (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Female (%)</td>
</tr>
<tr>
<td>NMD</td>
<td>51</td>
<td>59±17</td>
<td>28 (54.9)</td>
</tr>
<tr>
<td>OSA</td>
<td>120</td>
<td>58±14</td>
<td>80 (66.7)</td>
</tr>
<tr>
<td>COPD</td>
<td>16</td>
<td>69±9</td>
<td>14 (87.5)</td>
</tr>
<tr>
<td>HF</td>
<td>9</td>
<td>75±16</td>
<td>7 (77.8)</td>
</tr>
<tr>
<td>Other conditions</td>
<td>69</td>
<td>47±14**</td>
<td>27 (39.1)</td>
</tr>
</tbody>
</table>

*, P<0.05; **, P<0.001 compared to NMD, respectively. NMD, neuromuscular disease; OSA, obstructive sleep apnoea; COPD, chronic obstructive pulmonary disease; HF, heart failure.

Results

A total of 298 patients participated, of which data from 33 individuals were excluded based on incomplete datasets, to result in a cohort size of 265 patients. This cohort consisted of 51 patients with NMD (40 of which had SDB), 120 patients with OSA, 16 patients with COPD (14 of which had SDB), 9 patients with HF (7 with SDB), and 69 patients with other conditions. These groups were differences in the age distribution of the different groups; in particular, patients with non-respiratory disorders were significantly younger than patients with NMD. All but the non-respiratory disorder group contained more male than female subjects (Table 1).

Comparison of the SiNQ-5 scores between the subgroups did not show any statistically significant differences (P=0.077); patients with NMD and SDB who were established on NIV scored similar to patients with NMD who had not developed SDB (Figure 1).

Out of the total cohort, 148 patients completed the ESS. These were patients with OSA (n=78), patients with other conditions (n=60), and patients with NMD (n=10). In OSA patients, a positive correlation was found between ESS and SiNQ-5 scores (r=0.472; P<0.001), but there were no
Table 2 SiNQ-5 scores by leading diagnosis categorised as the number of patients scoring between 0–4 and 5–10 points

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Total score</th>
<th>0–4 points (%)</th>
<th>5–10 points (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMD with controlled SDB</td>
<td>40</td>
<td>3.4±3.0</td>
<td>28 (70.0)</td>
<td>12 (30.0)</td>
</tr>
<tr>
<td>NMD without SDB</td>
<td>11</td>
<td>2.7±2.9</td>
<td>8 (72.7)</td>
<td>3 (27.3)</td>
</tr>
<tr>
<td>OSA</td>
<td>120</td>
<td>4.1±2.6</td>
<td>68 (56.7)</td>
<td>52 (43.3)</td>
</tr>
<tr>
<td>COPD</td>
<td>16</td>
<td>3.9±3.0</td>
<td>10 (62.5)</td>
<td>6 (37.5)</td>
</tr>
<tr>
<td>HF</td>
<td>9</td>
<td>3.2±2.8</td>
<td>7 (77.8)</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>Other conditions</td>
<td>69</td>
<td>3.0±2.4</td>
<td>51 (73.9)</td>
<td>18 (26.1)</td>
</tr>
</tbody>
</table>

There were no significant differences in the ratio of patients scoring high or low between the groups (P>0.05). SD, standard deviation; NMD, neuromuscular disease; SDB, sleep-disordered breathing; OSA, obstructive sleep apnoea; COPD, chronic obstructive pulmonary disease; HF, heart failure.

Discussion

 Patients with neuromuscular conditions who develop SDB score similar on the SiNQ-5 compared to NMD patients without SDB once they are successfully established on NIV. SiNQ-5 scores of patients with NMD compared to patients with OSA and other conditions associated with breathlessness did not identify significant differences. Analysis of SiNQ-5 scores by individual questions revealed that particularly item #1 identified patients with NMD conditions. This item is focused on the development of postural breathlessness. Item #2 assessed whether patients felt breathless when bending forward, such as the motion required in tying shoelaces, and patients with OSA who were more obese than the other subgroups were identified by this question. An association between the ESS and the
SiNQ-5 scores potentially indicates that sleep disruption caused daytime symptoms, but this was only shown in the sleep apnoea cohort. These findings add understanding to previous work by the group, which demonstrated accuracy of the SiNQ-5 in identifying patients with NMD at risk of developing SDB (10).

Clinical relevance

A change from the seated to the supine posture has previously been described to result in a reduction of the functional residual capacity (FRC) (17,18). However, a decrease in the operating lung volume, combined with a shift of the abdominal contents with gravity impacting on a weak diaphragm can further contribute to worsening respiratory function when supine (19,20). Due to the obesity epidemic (21-23), OSA is the most common respiratory sleep disorder (17). Various questionnaires exist to screen patients for patients with OSA (2), the most common examples include the Berlin Questionnaire, which screens for sleep apnoea in the primary care setting (24), the ESS (5), and the STOP-BANG questionnaire, which specifically screens for OSA (25,26). In contrast to sleep apnoea, there are scarce tools to screen for respiratory sleep disorders in NMD. However, the existing clinical need for a questionnaire in NMD has led to the development of the SiNQ-5 (10).

Screening for SDB in NMD can be challenging owing to the wide spectrum of conditions (1,2). However, SDB has been highlighted as a common feature of patients with a weak diaphragm (20). Convincingly, management of SDB in NMD with NIV leads to significant improvements in the AHI, oxygenation, hypoventilation and symptom control, improving quality of life and reducing disease-related mortality (7,27,28). Hence, early detection and treatment of the condition is important. Indeed, in progressive NMD like motor neuron disease (MND), unmanaged SDB can result in respiratory failure and death (27).

The SiNQ-5 may be useful in guiding clinical decision making, but it is no adequate replacement for PSG studies. However, a high score in the SiNQ-5 (5–10 points) is a risk indicator for SDB in NMD patients, and can help to support the decision to refer for PSG or to guide timely intervention. In this context, the SiNQ-5 should be used alongside standard lung function tests and careful history taking (1,2,27), as well as arterial blood gas analysis.

Notably, no significant differences were found between NMD patients with controlled SDB and NMD patients without SDB. This finding may be interpreted as evidence that once controlled with NIV, symptoms of SDB were alleviated to the extent that no differences could be found when compared to NMD patients without respiratory muscle involvement. The varied nature of different NMD requires further investigation to determine whether the SiNQ-5 could be used to monitor disease progression or improvements during setup of NIV.

Limitations of the study

Patients in the current study cohort were included from clinic visits in the outpatient settings and PSG services. This method of sampling offered a realistic snapshot of questionnaire responses in a standard clinical setting. However, this will also have led to unequal sample sizes in different subgroups and selection bias. Furthermore, NMD patients with SDB were already established on NIV. Ideally, an experiment design would select for equal numbers of NMD patients with and without SDB and assess patients prior to and following setup on NIV to see whether the SiNQ-5 score is responsive to a change in the clinical circumstances. NMD patients with controlled SDB were determined as such with sleep studies or overnight pulse oximetry on therapy, and a review of whether SDB had been controlled or was still present. However, variations in the degree of control and treatment adherence, as well as in the patients’ perceived symptomatic improvement could have confounded the SiNQ-5 scores. Quantitative measures of the degree of control obtained in a sleep laboratory setting would have been useful in addressing these limitations.

Conclusions

Patients with NMD and SDB who are well controlled with NIV cannot be identified by means of the SiNQ-5. Further studies are necessary to further explore the responsiveness of the questionnaire when clinically monitoring patients with newly diagnosed NMD and SDB prior to commencing on NIV.

Acknowledgements

Dr. J Steier’s contribution to this work was partially supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital.
London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study was registered as a clinical service evaluation with the local clinical governance committee (registration number with local board: 2012-2979); informed, verbal consent was obtained from all participants.

References


